The impact of FDG positron emission tomography imaging on the management of lymphomas

British Journal of Radiology

Volumn 73, Issue 869, 2000, Pages 482-487

  Shah, N ^a   Hoskin, P ^a   McMillan, A ^a   Gibson, P ^a   Lowe, J ^a   Wong, W L ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IOPAMIDOL;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; IMAGING; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY;

EID: 0034023608     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.73.869.10884743     Document Type: Article

References (15)

1. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203: 795-800.
2. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-6.
3. Stumpe KDM UM, Steinert HC, Glanzman Ch, Buck GK, von Schulthess GK. Whole body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-8.
4. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
5. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49: 2112-35.
6. Sagel S, Glazer H. Mediastinum. In: Lee J, Sagel S, Stanley R, editors. Radiation oncology (2nd edn). New York: Ravens Press. 1995:245-94.
7. Pilepich M, Wong J, Wasserman T. CT with MR correlation. In: Lee J, Sagel S, Stanley R. editors. Radiation oncology (2nd edn). New York: Ravens Press, 1995:1101-11.
8. Stomper PC, Cholewinski SP, Park J, Bakshi SP, Barcos MP. Abdominal staging of thoracic Hodgkin disease: CT-lymphangiography-Ga-67 scanning correlation. Radiology 1993;187:381-6.
9. Cooper DL, Caride VJ, Zloty M, Germino J, Farber LR, Hoffer PB. Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy. J Clin Oncol 1993;11:1092-8.
10. Warburg O. The metabolism of tumours. London: Constable & Co, 1930.
11. Silverman DH, Hoh CK, Seltzer MA, Schiepers C, Cuan GS, Gambhir SS, et al. Evaluating tumor biology and oncological disease with positron-emission tomography. Semin Radiat Oncol 1998;8: 183-96.
12. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987;28:288-92.
13. Kubota K, Yamada K, Yoshioka S, Yamada S, Ito M, Ido T. Differential diagnosis of idiopathic fibrosis from malignant lymphadenopathy with PET and F-18 fluorodeoxyglucose. Clin Nucl Med 1992;17:361-3.
14. Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343-8.
15. Neal A, Hoskin P. Clinical oncology: basic principles and practice (2nd edn). London: Edward Arnold, 1998.